Recently, Beijing Hope Pharmaceutical Technology Co., Ltd. (“Hope”) announced that it has completed a total of RMB 40 million in financing. The financing was funded by Shenzhen Tongchuang Weiye Asset Management Co., Ltd. The funds raised will be mainly used in innovative drug discovery and incubation and generic drug development, drug and drug business development at home and abroad, clinical trial research platform construction, drug development software and hardware construction and talent team construction.
Established in 2005, Hope is a high_tech enterprise with chemical drug research and development as its core. It is mainly engaged in research and development, production, sales, technology transfer and technical services of chemical raw materials, pharmaceutical intermediates and pharmaceutical preparations. Haibu Medicine has consistently focused on chemical drug research and development. It has grown into a leading pharmaceutical formulation technology development and technical service company in China. It is also a leading R&D and sales company of APIs and intermediates.
By the end of 2017, Hope Pharmaceutical has provided high_quality intermediates and APIs to nearly 100 domestic and foreign pharmaceutical companies including Shijiazhuang Group, Jiangsu Haosen, Hisun Pharmaceutical, MSN, Hetero, Sun, etc. The company provides more than 100 formulations technology transfer and technical services.
Hope closely follows the development trend of international medicine, combines national policy adjustments, continuously improves the company's technology research and development strength, continuously optimizes the drug development process, strengthens data information construction, ensures the scientific and normative nature of drug research and development, and realizes drug technology research and development. Leaping Development. The technical details of Hope's intensive pharmacy research and development, and also try to cooperate in the field of bioequivalence, which is the key link to verify the quality and efficacy of generic drugs, so as to completely control the entire chain of consistency evaluation and strictly guarantee the quality and efficacy of generic drugs. On the basis of strengthening the development of generic drugs, Haibu Medicine strives to create innovative drug pipelines in the fields of psychology and anti_tumor, and through the independent research and development and cooperation to develop various models to shape the company's innovative ability; in the bulk drugs and intermediates Production technology actively uses cutting_edge chemical conversion technology and synthetic processes, including enzyme catalytic technology and continuous flow reaction technology, etc., thereby increasing production efficiency, reducing production costs and meeting the requirements of green chemistry.
Liu Changru, founder and chairman of Hope, said: “Hope focuses on R&D and technology, focusing on the field of chemical drugs. Drug development is a rigorous scientific practice, complex and time_consuming, and it tests our Only learn and test our will and collaboration. Every job we do will play a vital role in the safety, effectiveness, cost and price of drugs. Every Hope researcher With the awe of life, we must adhere to the spirit of scientific rigor, truth_seeking and pragmatism in every research and development process, and strive to perfect the technology and products."
When talking about this financing, Liu Changru said: "We are honored to receive the attention of investors, and we are fortunate to have been highly praised by Tongchuang Weiye for the steady development of Hope since its establishment more than ten years. In the rapid advancement of technology and market Under the background of rapid changes, new technologies, new methods, new models, and new products are emerging one after another. Haibu Medicine should open its mindset, broaden its thinking, actively innovate, and actively seek change, and quickly transform technology and knowledge into products. With the efforts of employees and the help of capital, the company will realize the profitability of the company and reflect the value of the company. The financing assisted by Tongchuang Weiye will greatly promote the rapid development of Haibu Medicine in accordance with the strategic layout and promote the development of Haibu Pharmaceutical business to a new level. height."
Hope in the eyes of investors
Yan Bin, the investment director of Tongda Weiye, said: “Hope has a high_level R&D team, strict scientific research management system, diversified service system and international development vision. We are optimistic about the huge Haibu medicine. The value of the platform is willing to accompany and support its development, jointly promote the development of China's chemical and pharmaceutical industry, and win the trust and respect of patients, doctors and society."
Beijing Hope Pharmaceutical Technology Co., Ltd. (stock short name: Hope, stock code: 836438) was founded in 2005 in Beijing Economic and Technological Development Zone. It is a high_tech enterprise with a focus on chemical drug research and development. The company is mainly engaged in research and development, production, sales, technology transfer and technical services of chemical raw materials, pharmaceutical intermediates and pharmaceutical preparations. It owns two wholly_owned subsidiaries of Beijing Haimeitong and Beijing Haimeiyuan.
Hope has more than 4,000 square meters of laboratories, nearly 200 people's research and development team, 32% of masters and above, equipped with conventional instruments and high_end equipments such as chemical synthesis, preparation, analysis, etc., from small to pilot scale, complete range, Provides adequate protection for high quality research and development. Research and development work has been carried out in various fields such as anti_tumor, depression, cardiovascular and cerebrovascular, digestive system, and respiratory medicine, and many research results have been obtained.
About Tongchuang Weiye
Tongchuang Weiye is China's first batch of professional private equity investment companies with 17 years of asset management experience, and its asset management scale ranks among the top in the industry. The company's long_term focus on venture capital investment is a domestic brand professional investment institution with leading position, long operating time and excellent return.